XTNT

Xtant Medical Holdings, Inc.

NYSE · Surgical & Medical Instruments & Apparatus · Inc. DE · CIK 0001453593
$0.4400 +2.33% $61.7M
High Impact Filing (7/10)
Vol
Market Cap$61.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders12 funds
Inst. Value$2.0M
Inst. Activity1 buys / 1 sells
SEC Reports2
Exchange NYSE·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001453593·Prev Close $0.4300

Recent Activity

Apr 21, 2026 SEC
Xtant Medical reported full-year 2025 revenue of $133.9 million, a 14% year-over-year increase, and achieved profitabili
8-K — Impact 7/10
Apr 13, 2026 SEC
Xtant Medical signed an exclusive U.S. distribution agreement for Dilon's HEMOBLAST Bellows product, hiring 20 sales sta
8-K — Impact 6/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
919,860 shares ($721.2K)
Inst.
Equitable Holdings, Inc. — TRIM
11,450 shares ($9.0K)
May 13, 2026 earnings_calendar
XTNT Q1 2026 Earnings Scheduled — 2026-05-13

Price Targets

$1.23 +180.3% upside Strong Buy
Current $0.4400 Low $1.00 Median $1.20 High $1.50 3 analysts
$1.00 $1.50

Analyst Ratings

Strong Buy89% buy · 9 analysts
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 13, 2026 BTIG REITERATE Buy → Buy
Mar 31, 2026 BTIG MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.02 ▼ -100.0% $-0.02 — $-0.02 -167% YoY 2
Next Q $-0.01 $-0.02 — $0.00 -172% YoY 2
Current FY $-0.08 ▼ -60.0% $-0.08 — $-0.08 -318% YoY 1
Next FY $-0.01 ▲ +75.0% $-0.03 — $0.02 94% YoY 2

Latest Reports

MIXED 8-K 7/10
Xtant Medical reported full-year 2025 revenue of $133.9 million, a 14% year-over-year increase, and achieved profitabili
Apr 21, 2026
MIXED 8-K 6/10
Xtant Medical signed an exclusive U.S. distribution agreement for Dilon's HEMOBLAST Bellows product, hiring 20 sales sta
Apr 13, 2026

Top Institutional Holders

FundValueMove
VANGUARD CAPITAL MANAGEMENT LLC$1.1M—
RENAISSANCE TECHNOLOGIES LLC$551.0KADD
VANGUARD FIDUCIARY TRUST CO$144.0K—
CITADEL ADVISORS LLC$89.8K—
BlackRock, Inc.$64.6K—
12 institutional holders with $2.0M total value (3,625,945 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, VANGUARD.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1VANGUARD CAPITAL MANAGEMENT LLC2,014,603$1.1M55.5%—
2RENAISSANCE TECHNOLOGIES LLC987,410$551.0K27.2%ADD +28.8%
3VANGUARD FIDUCIARY TRUST CO257,988$144.0K7.1%—
4CITADEL ADVISORS LLC161,011$89.8K4.4%—
5BlackRock, Inc.115,782$64.6K3.2%—
6STATE STREET CORP31,266$17.4K0.9%—
7SEI INVESTMENTS CO24,760$13.8K0.7%—
8LAZARD ASSET MANAGEMENT LLC19,562$10.9K0.5%—
9Equitable Holdings, Inc.11,450$9.0K0.4%TRIM -46.6%
10MORGAN STANLEY1,125$628.000.0%—
11FMR LLC500$279.000.0%—
12WELLS FARGO & COMPANY/MN488$272.000.0%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RENAISSANCE TECHNOLOGIES LLCADD713,915919,860+28.8%$721.2K2025-Q4
Equitable Holdings, Inc.TRIM21,45011,450-46.6%$9.0K2025-Q4
UBS Group AGDOUBLED1395+39400.0%$257.002025-Q3
BANK OF AMERICA CORP /DE/TRIM544393-27.8%$254.002025-Q3
UBS Group AGNEAR_EXIT39,0481-100.0%—2024-Q4
∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 0 neutral. Avg impact: 6.5/10.
MIXED 8-K 7/10
Xtant Medical reported full-year 2025 revenue of $133.9 million, a 14% year-over-year increase, and
Apr 21, 2026
MIXED 8-K 6/10
Xtant Medical signed an exclusive U.S. distribution agreement for Dilon's HEMOBLAST Bellows product,
Apr 13, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$1.23 mean target +180.3% upside Strong Buy (3.00)
$1.00 Low $1.50 High
MetricValue
Current Price$0.4400
Target Low$1.00
Target Mean$1.23
Target Median$1.20
Target High$1.50
# Analysts3
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.02 $-0.02 $-0.02 -167.3% -100.0% 0↑ 1↓ $0.0B -30.9% 2
Next Q
2026-09-30
 $-0.01 $-0.02 $0.00 -172.5% +0.0% 0↑ 1↓ $0.0B -17.8% 2
Current FY
2026-12-31
 $-0.08 $-0.08 $-0.08 -317.6% -60.0% 0↑ 1↓ $0.1B -23.5% 1
Next FY
2027-12-31
 $-0.01 $-0.03 $0.02 93.8% +75.0% 0↑ 1↓ $0.1B 9.4% 2

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.020
7d ago$-0.010-0.010
30d ago$-0.010-0.010
60d ago$0.000-0.020
90d ago$0.000-0.020
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 13, 2026 BTIG REITERATE Buy Buy
Mar 31, 2026 BTIG MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263510089%
May 1, 20263510089%
Apr 1, 20263410088%
Mar 1, 20263410088%
Feb 1, 20263410088%
Jan 1, 20263410088%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 13, 2026
earnings_calendar
XTNT Q1 2026 Earnings Scheduled — 2026-05-13
Apr 30, 2026
earnings_calendar
XTNT Q1 2026 Earnings Scheduled — 2026-04-30
Mar 31, 2026
earnings_calendar
XTNT Q4 2025 Earnings Before Market Open — 2026-03-31
Mar 20, 2026
earnings_calendar
XTNT Q4 2025 Earnings Before Market Open — 2026-03-20
Mar 5, 2026
earnings_calendar
XTNT Q4 2025 Earnings Before Market Open — 2026-03-05
Mar 4, 2026
earnings_calendar
XTNT Q4 2025 Earnings Before Market Open — 2026-03-04